Supriya Lifescience Ltd. Unveils Remarkable PAT Growth of 32% in FY24, Amidst 23.7% Revenue Surge

The unaudited financial statements for the fourth quarter of FY24 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.

Key Consolidated Financial Highlights: 

Key Highlights for FY24:

In FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 23.7% year-over-year increase, reaching Rs. 570.37 crores compared to Rs. 460.94 crores in FY23.

Gross Profit for FY24 stood at Rs. 348.63 crores, with a growth of 24.5% compared to Rs. 280.13 crores in FY23.

EBITDA for FY24 increased by 34.2% YoY to Rs. 172.97 crores, with an EBITDA Margin of 30.3%, as opposed to an EBITDA of Rs. 128.90 crores in FY23 with an EBITDA margin of 28.0%. 

The Profit After Tax (PAT) for FY24 at Rs 119.11 crore, compared to Rs 89.86 crore in FY23 an increase of 32.6%.

The PAT Margin improved from 19.5% in FY23 to 20.9% in FY24. 

The company’s business in Europe picked up this year, contributing 41% to the net revenue, compared to last year which stood at 33%. This led to a more balanced revenue distribution across regions. 

The Analgesic and Anaesthetic segment led the revenue growth and contributed to 46% of sales in FY24, compared to 44% last year. Vitamin segment also performed well contributing 13% compared to 11% last year. The contribution of the Anit-histamine segment remains robust at 15% of sales. 

Key Consolidated Financial Highlights: 

Key Highlights for Q4 FY24:

In the fourth quarter of FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting an 11.2 % year-over-year increase, reaching Rs. 158.18 crore compared to Rs. 142.27 crore in Q4 FY23.

Gross Profit for Q4 FY24 stood at Rs. 99.91 crore, with a growth of 5.5% compared to Rs. 94.71 crore in Q4 FY23.

EBITDA for Q4 FY24 stood at Rs. 55.50 crore, with an EBITDA Margin of 35.1%, as opposed to an EBITDA of Rs. 55.05 crore in Q4 FY23 with an EBITDA margin of 38.7%. This marks a growth of 0.8% YoY.

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23. 

The PAT Margin stood at 23.0% in Q4 FY24, compared to 26.9% in Q4 FY23.

Dr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd, commenting on the results, said, “Our unwavering commitment to quality, innovation, and strategic expansion has driven another year of remarkable growth. As we navigate through evolving landscapes, Supriya Lifescience remains steadfast in our mission to deliver excellence, enrich lives, and shape the future of healthcare."